***Background.*** Ceftaroline (CPT), the active metabolite of the prodrug CPT fosamil, is the first cephalosporin with potent activity against methicillin-susceptible (MSSA) and -resistant *S. aureus*(MRSA). CPT is approved for treatment of community-acquired penumonia and acute bacterial skin infections.

***Methods.*** 4,426 *S. aureus*isolates from the AWARE CPT surveillance program were derived from patients with bacteremia in 2009-2013. Isolates were collected in 150 medical centers distributed through all 9 USA Census regions, and tested for susceptibility (S) against CPT and comparators by the CLSI broth microdilution method. S interpretations were determined per CLSI criteria.

***Results.*** 45.5% of isolates were MRSA. CPT (MIC~50/90~, 0.25/1 µg/mL) inhibited 97.9 and 100.0% of *S. aureus* at ≤1 and ≤2 µg/mL, respectively (Table). Daptomycin (DAP; MIC~50/90~, 0.25/0.5 µg/mL), linezolid (LZD; MIC~50/90~, 1/2 µg/mL) and vancomycin (VAN; MIC~50/90~, 1/1 µg/mL) were active against ≥99.8% of isolates. S rates for erythromycin (MIC~50/90~, \>16/ \> 16 µg/mL), clindamycin (CLI; MIC~50/90~, ≤0.25/ \> 2 µg/mL) and levofloxacin (LEV; MIC~50/90~, ≤0.5/ \> 4 µg/mL) were 42.5, 80.8 and 59.2%, respectively. Against MSSA, CPT (MIC~50/90~, 0.25/0.25 µg/mL; 100.0% S) was 16-, 4- and 4-fold more active than ceftriaxone (MIC~50/90~, 4/4 µg/mL), LZD (MIC~50/90~, 1/2 µg/mL ) and VAN (MIC~50/90~, 1/1 µg/mL), respectively, and slightly more potent than DAP (MIC~50/90~, 0.25/0.5 µg/mL). Among MRSA, 95.4 and 100.0% of strains were inhibited at ≤1 and ≤2 µg/mL of CPT, respectively. 35.8% and 75.4% of MRSA were resistant to CLI and LEV, respectively. 99.7% of MRSA strains were DAP-S (MIC~50/90~, 0.25/0.5 µg/mL), and LZD (MIC~50/90~, 1/2 µg/mL) and VAN (MIC~50/90~, 1/1 µg/mL) were active against \>99.9% of MRSA strains.

  Organism (no.)        No. of isolates (cum. % inhibited at CPT MIC (µg/mL) of:                                                          
  --------------------- ---------------------------------------------------------- ----------- -------------- -------------- ------------ ------------
  *S. aureus* (4,426)   13 (0.3)                                                   222 (5.3)   2,105 (52.9)   1,113 (78.0)   880 (97.9)   93 (100.0)
  MSSA (2,413)          13 (0.5)                                                   221 (9.7)   2,067 (95.4)   111 (\>99.9)   1 (100.0)    \--
  MRSA (2,013)          0 (0.0)                                                    1 (0.0)     38 (1.9)       1,002 (51.7)   879 (95.4)   93 (100.0)

***Conclusion.*** Our results demonstrate the potent in vitro activity of CPT when tested against a large collection of contemporary (2008-2013) *S. aureus*isolates causing bacteremias in USA hospitals.
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